Glyscend is an innovative brand that offers a novel approach to treating Type 2 Diabetes and Metabolic Disease. They aim to provide the benefits of metabolic surgery without the risks, using a unique class of gut-targeted polymer therapies. Their dynamic barrier approach mimics the effects of gastric bypass surgery and duodenal exclusion devices, but without the need for invasive procedures.

Glyscend's drugs, based on a polymer therapeutic platform, are taken orally and can non-invasively replicate the physiology of bariatric surgery. Leveraging decades of experience in gastroenterology, metabolism, polymer chemistry, and drug development, Glyscend's team has contributed to over 25 FDA-approved therapeutic products. This includes groundbreaking treatments like Byetta®, Bydureon®, Renagel®, and Welchol®.

Stay up-to-date with Glyscend's latest news, including the availability of Phase 2a clinical results and the publication of GLY-200 First-in-Human Data. Learn more about their science and contact them for further information